Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter L Anderson

Showing results (121-130 of 271) with videos related to

Pageof 28
Sort By:
Journal of Pharmaceutical and Biomedical Analysis|September 24, 2013
Quantitation of tenofovir and emtricitabine in dried blood spots (DBS) with LC-MS/MSJia-Hua Zheng, Louis A Guida, Caitlin Rower, et al.
Contemporary Clinical Trials|July 10, 2026
Life-steps for PrEP nurse-delivered adherence intervention: Protocol for a multisite randomized clinical trialMarc Puccinelli, Kenneth H Mayer, Juan A Esquivel-Mendoza, et al.
Plos One|January 10, 2018
Comparing pharmacologic measures of tenofovir exposure in a U.S. pre-exposure prophylaxis randomized trialSanjiv M Baxi, Eric Vittinghoff, Peter Bacchetti, et al.
Open Forum Infectious Diseases|September 29, 2021
Low-Level Viremia Is Associated With Cumulative Adherence to Antiretroviral Therapy in Persons With HIVJose R Castillo-Mancilla, Mary Morrow, Ryan P Coyle, et al.
AIDS (London, England)|June 15, 2021
Emtricitabine triphosphate in dried blood spots predicts future viremia in persons with HIV and identifies mismatch with self-reported adherenceMary Morrow, Samantha MaWhinney, Ryan P Coyle, et al.
Frontiers in Reproductive Health|June 11, 2024
Establishing adherence-concentration-efficacy thresholds of TDF-FTC pre-exposure prophylaxis for HIV prevention in African women: a protocol for the Women TDF-FTC Benchmark StudyLinxuan Wu, Matilda Saina, Clare Brown, et al.
Journal of Neurovirology|January 9, 2019
Self-initiated continuation of and adherence to HIV pre-exposure prophylaxis (PrEP) after PrEP demonstration project roll-off in men who have sex with men: associations with risky decision making, impulsivity/disinhibition, and sensation seekingMartin Hoenigl, Erin Morgan, Donald Franklin, et al.
Journal of the International AIDS Society|April 8, 2025
Exploring potential drug-drug interactions between masculinizing hormone therapy and oral pre-exposure prophylaxis (F/TDF and F/TAF) among transgender men (iMACT study): a randomized, open-label pharmacokinetic study in ThailandAkarin Hiransuthikul, Narukjaporn Thammajaruk, Stephen Kerr, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 17, 2020
Failure of pre-exposure prophylaxis with daily tenofovir/emtricitabine and the scenario of delayed HIV seroconversionShui-Shan Lee, Peter L Anderson, Tsz-Ho Kwan, et al.
Pharmacotherapy|June 16, 2022
Cumulative tenofovir diphosphate exposure in persons with HIV taking single- vs. multiple-tablet regimensRyan P Coyle, Mary Morrow, Samantha MaWhinney, et al.
Pageof 28

Showing results (121-130 of 271) with videos related to

Sort By:
Pageof 28
Journal of Pharmaceutical and Biomedical Analysis|September 24, 2013
Quantitation of tenofovir and emtricitabine in dried blood spots (DBS) with LC-MS/MSJia-Hua Zheng, Louis A Guida, Caitlin Rower, et al.
Contemporary Clinical Trials|July 10, 2026
Life-steps for PrEP nurse-delivered adherence intervention: Protocol for a multisite randomized clinical trialMarc Puccinelli, Kenneth H Mayer, Juan A Esquivel-Mendoza, et al.
Plos One|January 10, 2018
Comparing pharmacologic measures of tenofovir exposure in a U.S. pre-exposure prophylaxis randomized trialSanjiv M Baxi, Eric Vittinghoff, Peter Bacchetti, et al.
Open Forum Infectious Diseases|September 29, 2021
Low-Level Viremia Is Associated With Cumulative Adherence to Antiretroviral Therapy in Persons With HIVJose R Castillo-Mancilla, Mary Morrow, Ryan P Coyle, et al.
AIDS (London, England)|June 15, 2021
Emtricitabine triphosphate in dried blood spots predicts future viremia in persons with HIV and identifies mismatch with self-reported adherenceMary Morrow, Samantha MaWhinney, Ryan P Coyle, et al.
Frontiers in Reproductive Health|June 11, 2024
Establishing adherence-concentration-efficacy thresholds of TDF-FTC pre-exposure prophylaxis for HIV prevention in African women: a protocol for the Women TDF-FTC Benchmark StudyLinxuan Wu, Matilda Saina, Clare Brown, et al.
Journal of Neurovirology|January 9, 2019
Self-initiated continuation of and adherence to HIV pre-exposure prophylaxis (PrEP) after PrEP demonstration project roll-off in men who have sex with men: associations with risky decision making, impulsivity/disinhibition, and sensation seekingMartin Hoenigl, Erin Morgan, Donald Franklin, et al.
Journal of the International AIDS Society|April 8, 2025
Exploring potential drug-drug interactions between masculinizing hormone therapy and oral pre-exposure prophylaxis (F/TDF and F/TAF) among transgender men (iMACT study): a randomized, open-label pharmacokinetic study in ThailandAkarin Hiransuthikul, Narukjaporn Thammajaruk, Stephen Kerr, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 17, 2020
Failure of pre-exposure prophylaxis with daily tenofovir/emtricitabine and the scenario of delayed HIV seroconversionShui-Shan Lee, Peter L Anderson, Tsz-Ho Kwan, et al.
Pharmacotherapy|June 16, 2022
Cumulative tenofovir diphosphate exposure in persons with HIV taking single- vs. multiple-tablet regimensRyan P Coyle, Mary Morrow, Samantha MaWhinney, et al.
Pageof 28